Ellington Management Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

Ellington Management Group’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-23,300	Closed	-$303K	–	786
2019 Q3	$303K	Buy	+23,300	New	+$285K	0.05%	368
2019 Q2	–	Sell	-11,100	Closed	-$175K	–	817
2019 Q1	$175K	Buy	+11,100	New	+$192K	0.03%	489
2017 Q2	–	Sell	-16,400	Closed	-$341K	–	943
2017 Q1	$341K	Buy	+16,400	New	+$337K	0.01%	427
2015 Q3	–	Sell	-19,100	Closed	-$611K	–	932
2015 Q2	$611K	Buy	+19,100	New	+$491K	0.15%	188

Other funds holding RVNC

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

NCM

NovaQuest Capital Management Raleigh, North Carolina $54.3M AUM 163.39% 1-Year Est. Return

Ellington Management Group's RVNC Position: Q4 2019 in Review

Ellington Management Group sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2019, closing a stake of 23,300 shares — an estimated $303K sold.

Ellington Management Group first reported a position in RVNC in Q2 2015 and held it in 4 quarters. The position peaked at $611K in Q2 2015. 134 funds tracked by Wall St. Rank hold RVNC as of Q4 2019.

Ellington Management Group reported no remaining Revance Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
Ellington Management Group sold 23,300 Revance Therapeutics, Inc. shares in Q4 2019, an estimated $303K.
Ellington Management Group first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 4 quarters.
Ellington Management Group's Revance Therapeutics, Inc. position peaked at $611K in Q2 2015.
134 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2019.

Based on Ellington Management Group's 13F filing for Q4 2019, filed 14 Feb 2020.